



MEMORANDUM

TO: Local Health Department Administrators
All Illinois Vaccine Providers

FROM: IDPH Immunization Section

DATE: August 27, 2024

RE: **2024-25 COVID-19 Vaccines Ordering**

2024-25 COVID-19 VACCINES

On August 22, 2024, the [FDA approved and granted emergency use authorization \(EUA\) for updated mRNA COVID-19 vaccines \(2024-2025 formula\)](#) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.

These actions relate to updated mRNA vaccines for 2024–2025 manufactured by ModernaTX Inc. and Pfizer Inc., which have been updated to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain.

- Pfizer-BioNTech COVID-19 Vaccine (2024–2025 Formula): individuals ages 6 months and older
- Moderna COVID-19 Vaccine (2024–2025 Formula): individuals ages 6 months and older

The 2023–2024 Novavax COVID-19 vaccine remains authorized but is **no longer available in the United States, as all doses have expired**. Accordingly, at this time, CDC recommendations for use of Novavax COVID-19 vaccine have been removed. CDC recommendations will be updated if FDA approves or authorizes additional 2024–2025 COVID-19 vaccines.

USE OF COVID-19 VACCINES IN THE U.S.

CDC has recently updated the clinical considerations [Clinical Guidance for COVID-19 Vaccination | CDC](#).

Recommendations for 2024–2025 Moderna COVID-19 Vaccine and 2024–2025 Pfizer-BioNTech COVID-19 Vaccine

People who are not moderately or severely immunocompromised

Initial vaccination

- Ages 6 months–4 years
 - 2 doses of 2024–2025 Moderna or 3 doses of 2024–2025 Pfizer-BioNTech
- Ages 5 years and older
 - 1 dose of 2024–2025 Moderna or 1 dose of 2024–2025 Pfizer-BioNTech

Received previous doses of a COVID-19 vaccine

- Ages 6 months–4 years
 - 1 or 2 doses of 2024–2025 mRNA vaccine from the same manufacturer as administered for initial vaccination, depending on the vaccine and the number of prior doses
- Ages 5 years and older
 - 1 dose of 2024–2025 Moderna or 1 dose of 2024–2025 Pfizer-BioNTech

Additional dose: An additional dose of 2024–2025 COVID-19 vaccine for people ages 65 years and older who are not moderately or severely immunocompromised is NOT currently recommended.

People who are moderately or severely immunocompromised

Initial vaccination

- Ages 6 months and older
 - 3 doses of 2024–2025 Moderna or 3 doses of 2024–2025 Pfizer-BioNTech

Received previous doses of a COVID-19 vaccine

- Recommended mRNA vaccine and number of 2024–2025 doses are based on age and vaccination history

Additional doses: People who are moderately or severely immunocompromised ages 6 months and older may receive 1 or more age-appropriate doses of a 2024–2025 mRNA COVID-19 vaccine.

ORDERING COVID-19 FOR PUBLICLY FUNDED PROGRAMS

For updated COVID-19 vaccines:

- Ordering for the updated Pfizer COVID-19 vaccines listed below is now open.

Manufacturer	Presentation	Unit of Sale NDC
Pfizer Inc.	12y+; SYR; 10pk	00069-2432-10
Pfizer Inc.	Ped 5y-11y; SDV; 10pk	59267-4438-02
Pfizer Inc.	Ped 6m-4y; MDV3; 10pk*	59267-4426-02

*Shipping for Pfizer’s pediatric presentation for children 6m-4y is expected to begin Sept. 4, 2024.

PROTECTING HEALTH, IMPROVING LIVES

Nationally Accredited by PHAB

- Ordering for the updated Moderna COVID-19 vaccines listed below are anticipated to be open next week. Communication will be sent when this is available for ordering.

Manufacturer	Presentation	Unit of Sale NDC
ModernaTX Inc.	12y+; SYR; 10pk	80777-0110-93
ModernaTX Inc.	Ped 6m-11y; SYR; 10pk	80777-0291-80

- Ordering for Novavax vaccine will be available at a future date. Communication will be sent at that time.

LIMITED QUANTITY ORDERING

The Illinois Department of Public Health (IDPH) is committed to ensuring providers have COVID-19 vaccine available as early as possible for the upcoming season. A plan has been established to ensure that vaccine is available to VFC and AIP sites who need it in the early part of the season while manufacturers build up stock at distribution centers.

COVID-19 Vaccine Ordering Timeline

COVID-19 vaccines for the VFC and Section AIP programs are beginning to come in as the CDC allocates vaccines to the State of Illinois and other jurisdictions. These vaccines are allocated in limited quantities in the early season.

For providers that want to have vaccine inventory early in the season, we have established an early season ordering process. **This new process is effective immediately.** This will only be in place early in the season while supplies are available in limited quantities. We will review orders and allocate vaccines based on the Illinois vaccine allocation, your current vaccine inventory, and your past ordering practices. Once, vaccine supplies are built up, we will send out an additional notification that COVID-19 vaccines will be available for regular ordering with your routine VFC or AIP program vaccines. If you have a special event such as a community clinic coming up, please let us know so we can attempt to accommodate your request. COVID-19 vaccine administration from last season will be taken into account when determining your order for this season.

Be Prepared for Order Review

To ensure that your order can be processed without delay, please be sure to update your temperature logs, data logger certificates of calibration, vaccine coordinator training certificates, and vaccine inventory.

Limited Quantity Orders

All limited-quantity orders will be reviewed and processed weekly. If orders cannot be filled due to supply constraints, order quantities will be reduced and filled at the quantities available. IDPH vaccine supply will be posted in I-CARE. **Once vaccines supplies are built up, we will send out an additional notification that COVID-19 vaccines will be available for regular ordering with your routine VFC or AIP program vaccines.**

EARLY SEASON ORDERING PROCESS

- 1) Open the order form from the VFC tab as you normally would. In the Order Intent field, select **Pediatric/VFC Limited Qty** for VFC COVID-19 vaccines or **Adult/317 Limited Qty** for AIP COVID-19 vaccines.

All Limited Quantity orders will be reviewed and processed by the VFC Program. Every attempt will be made to fill limited quantity orders at the quantities requested. If, due to supply constraints, orders cannot be completely filled, order quantities will be reduced and filled at the quantities available.

Order Intent: Pediatric/VFC Adult/317
 Pediatric/VFC Limited Qty Adult/317 Limited Qty

- 2) Please select the vaccine and enter the quantities you anticipate needing for the upcoming month. Change your order status to Requested as you normally do.
- 3) Once your order is saved, the order will be identified as a limited quantity order.

1812390	07/31/2023	Requested > IDPH action required	07/31/2023	VFC Limited Order: 4 vaccines; 40 doses
-------------------------	------------	--	------------	---

- 4) On a weekly basis, IDPH will review its COVID-19 vaccine allocations from CDC and will approve requests as inventory allows. The vaccine coordinator will receive an email via I-CARE regarding any approvals, quantity reductions, or other needs.
- 5) If your order was reduced or if you need more vaccine, you may place a new order the following week.

EXISTING 2023-2024 COVID-19 VACCINES

As part of FDA’s actions, the 2023–2024 Moderna and Pfizer-BioNTech COVID-19 vaccines are **no longer authorized** for use in the United States. To minimize the risk of [vaccine administration errors](#), providers should:

- Remove all 2023–2024 mRNA COVID-19 vaccines from storage units immediately, even if they are not expired.
- Once all publicly funded vaccine inventory is fully accounted for, delete 2023–2024 mRNA COVID-19 vaccine listings from the available vaccine inventory in I-CARE.
- For convenience, all remaining inventory in I-CARE will be marked as out-of-stock on or about September 6, 2024. Please ensure all doses are accounted for by this date.
- VFC and Bridge vaccines remaining on-hand should be returned to CDC’s centralized distributor using the normal process for returning spoiled/expired vaccines.

BRIDGE ACCESS PROGRAM ENDING

Effective immediately the 2023-2024 COVID-19 vaccines are no longer available, and the BRIDGE Program has officially ended.

Providers that are eligible to participate in the Adult Immunization Program (AIP) program can also receive 2024-2025 COVID-19 vaccines in addition to other adult routine vaccines. Local Health Departments, Rural Health Centers, and FQHCs are automatically enrolled in AIP if they are also VFC Providers. Local Health Departments, Rural Health Centers, and FQHC providers that do not participate in VFC can reach out to dph.vaccines@illinois.gov.

Program Comparison

Note that first-dollar coverage has been added to the definition of underinsured patients for the AIP Program effective August 23, 2024. This will be added to the IDPH AIP manual shortly to reflect this change.

	Adult Immunization Program (AIP)	Bridge Program
Age	19 years and older	18 years and older
Uninsured	Yes	Yes
Underinsured	Refers to a person who: <ul style="list-style-type: none"> • has health insurance, but the insurance does not cover any vaccines; • a person whose insurance covers only selected vaccines; • a person whose insurance does not provide first-dollar coverage for vaccines. 	Refers to a person who: <ul style="list-style-type: none"> • has health insurance, but the insurance does not cover COVID-19 vaccines; • a person whose medical insurance does not provide first-dollar coverage (i.e., copay-free coverage) of COVID-19 vaccinations.

RESOURCES

- [Comirnaty \(COVID-19 Vaccine, mRNA\) \(2024-2025 Formula\)](#)
- [Spikevax \(COVID-19 Vaccine, mRNA\) \(2024-2025 Formula\)](#)
- [Moderna COVID-19 Vaccine \(2024-2025 Formula\)](#)
- [Pfizer-BioNTech COVID-19 Vaccine \(2024-2025 Formula\)](#)
- [FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants|CDC](#)
- [FDA Resources for the Fall Respiratory Illness Season](#)
- [Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024](#)
- [June 5, 2024, Meeting of the Vaccines and Related Biological Products Advisory Committee](#)

CONTACT US FOR MORE INFORMATION

For help, questions or feedback please contact the IDPH Immunization Section at dph.vaccines@illinois.gov or call 217-785-1455 and select option 2.